Abstract 220P
Background
Radiation oral mucositis (radiotherapy-induced oral mucositis, RIOM), as one of the common complications during radiotherapy, is difficult to avoid and predict. Severe RIOM will reduce the quality of life of patients and affect the normal progress of diagnosis and treatment. Early detection and early intervention is very important to reduce the incidence of RIOM, but at present, the sensitivity and specificity of clinical indicators for the occurrence and development of radiation stomatitis are poor, so it is necessary to study further the treatment factors and predictive indicators of radiation stomatitis. It has been found that oral flora are closely related to the progression of radiation oral mucositis.
Methods
27 postoperative patients with oral squamous cell carcinoma were enrolled in the study. The cotton swab samples of oral buccal mucosa before and after radiotherapy were collected. The diversity, species differences and marker species of the oral microbial community were determined by 16 S rRNA sequencing and metagenome sequencing.
Results
Compared with the pre-radiotherapy group, the composition of oral flora in the radiotherapy group and the post-radiotherapy group changed, and the community diversity decreased significantly. The richness of different flora was different. In terms of genera, there was a difference in the richness of Haemophilus during radiotherapy, after radiotherapy and before radiotherapy, and the number of different bacteria was positively correlated with the time of radiotherapy. At the species level, the diversity of Streptococcus pneumoniae and Haemophilus haemolyticus increased significantly after radiotherapy. In terms of functional distribution, based on KEGG and CAZymes database, there were differences in functional distribution between the two groups of oral flora.
Conclusions
Radiotherapy can change the species structure and composition of oral flora and reduce community diversity. Streptococcus pneumoniae and Haemophilus haemolyticus may be related to the occurrence and development of radiation oral mucositis.
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
76P - Fixed 2-year vs. continuous duration immune checkpoint inhibitors in patients diagnosed with advanced cancer: to continue or not to continue?
Presenter: Miles Smith
Session: Poster Display session
77P - A new prognostic index for patients with advanced BTC treated with cisplatin, gemcitabine and durvalumab
Presenter: MARA PERSANO
Session: Poster Display session
79P - Relevance of combined positive score (CPS) & low-dose immune checkpoint inhibitors (ICIs) in microsatellite stable (MSS) advanced gastric adenocarcinoma (GC): A multi-institution analysis
Presenter: Anant Ramaswamy
Session: Poster Display session
80P - Tumor markers evolution in pts treated with TCE and association with radiologic response
Presenter: Constance d'Abrigeon
Session: Poster Display session
Resources:
Abstract
81P - Predictive value of inflammatory ratios on the outcome of advanced melanoma patients treated with anti-PD1 monotherapy: A multicentric analysis
Presenter: Aleksandar Popovic
Session: Poster Display session
82P - Predictive biomarkers for neoadjuvant immunochemotherapy efficacy in locally advanced cancer patients: A retrospective analysis based on changes in tumor shrinkage rate and lymphocyte count
Presenter: Zhanjie Zhang
Session: Poster Display session
83P - Effectiveness and safety of neoadjuvant immunochemotherapy with and without surgery in patients with resectable esophageal squamous cell carcinoma: A retrospective cohort study
Presenter: xuqiang liao
Session: Poster Display session
84P - Safety Of Treatment With Immune Checkpoint Inhibitors In Older Adults With Non-Small Cell Lung Cancer
Presenter: Verene Dougoud-Chauvin
Session: Poster Display session
86P - Treatment trajectories and outcome following irAE related hospitalization in metastatic cancer patients
Presenter: Veera Nurmela
Session: Poster Display session
87P - Access to vedolizumab for the management of immune-related colitis (IRC): A United Kingdom study
Presenter: Faye Coe
Session: Poster Display session